Baidu
map

Cell:我国科学家将适应性免疫的起源向前推进1亿年

2016-07-29 申安妮 王凯蕾 新华社

近日,我国科学家的一项发现将适应性免疫的起源向前推进1亿年,这将改写现行免疫学教科书。 在国家自然科学基金委和科技部高技术发展计划(863)和国家重大基础研究发展计划(973)的资助下,中山大学徐安龙教授领导的研究团队发现了6亿年前重组激活基因转座子的“分子活化石”,为“人类抗体重排机制的转座子起源假说”提供了最有力的证据。 根据中山大学生命科学学院官网的介绍,人体的免疫系统分为两

近日,我国科学家的一项发现将适应性免疫的起源向前推进1亿年,这将改写现行免疫学教科书。

在国家自然科学基金委和科技部高技术发展计划(863)和国家重大基础研究发展计划(973)的资助下,中山大学徐安龙教授领导的研究团队发现了6亿年前重组激活基因转座子的“分子活化石”,为“人类抗体重排机制的转座子起源假说”提供了最有力的证据。

根据中山大学生命科学学院官网的介绍,人体的免疫系统分为两部分:先天的固有免疫和后天可改变的适应性免疫。抗体重排机制就是适应性免疫中,后天能应对无数病源侵害的最关键机制。徐安龙的团队发现文昌鱼保留了决定抗体重排机制的转座子,也就是可自主复制和位移的DNA序列。

据介绍,这一发现为人类抗体重排的转座子起源假说提供了最强有力和直接的证据,该转座子的发现还为未来利用重排机制设计新的免疫抗体和免疫基因提供了崭新的基因编辑思路和技术。从免疫学的大视野看,该发现将适应性免疫的起源由脊椎动物推前到无脊椎脊索动物文昌鱼,由此向前推进1亿年,这将改写现行免疫学教科书关于适应性免疫起源的观点。

该研究成果形成论文日前发表在国际生物类著名期刊《细胞》上。

原始出处

 Shengfeng Huang8, Xin Tao8, Shaochun Yuan8, Yuhang Zhang, Peiyi Li, Helen A. Beilinson, Ya Zhang, Wenjuan Yu, Pierre Pontarotti, Hector Escriva, Yann Le Petillon, Xiaolong Liu, Shangwu Chen, David G. Schatz.Discovery of an Active RAG Transposon Illuminates the Origins of V(D)J Recombination.Cell.2016 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959742, encodeId=5e111959e429c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 10 12:59:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814220, encodeId=dd8f18142202a, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Oct 28 04:59:00 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869484, encodeId=40bd186948478, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 22 18:59:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620998, encodeId=9aa3162099804, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Sun Jul 31 06:59:00 CST 2016, time=2016-07-31, status=1, ipAttribution=)]
    2017-01-10 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959742, encodeId=5e111959e429c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 10 12:59:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814220, encodeId=dd8f18142202a, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Oct 28 04:59:00 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869484, encodeId=40bd186948478, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 22 18:59:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620998, encodeId=9aa3162099804, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Sun Jul 31 06:59:00 CST 2016, time=2016-07-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959742, encodeId=5e111959e429c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 10 12:59:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814220, encodeId=dd8f18142202a, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Oct 28 04:59:00 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869484, encodeId=40bd186948478, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 22 18:59:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620998, encodeId=9aa3162099804, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Sun Jul 31 06:59:00 CST 2016, time=2016-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959742, encodeId=5e111959e429c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 10 12:59:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814220, encodeId=dd8f18142202a, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Oct 28 04:59:00 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869484, encodeId=40bd186948478, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Mar 22 18:59:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620998, encodeId=9aa3162099804, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Sun Jul 31 06:59:00 CST 2016, time=2016-07-31, status=1, ipAttribution=)]

相关资讯

p16/Ki-67双染检测助力宫颈癌前病变诊断

研究发现,全球99%以上的宫颈癌病例都是由人乳头瘤病毒(HPV)所引起,只有长期持续感染高危型HPV病毒才会导致高级别宫颈上皮内瘤变(CIN),进而发展为宫颈癌。由此,宫颈癌防治的关键在于筛查出高风险人群,找出高级别CIN患者,及时干预。采用免疫组化双染技术在宫颈上皮细胞或组织中检测两种生物标志物p16和Ki-67以辅助诊断宫颈癌前病变已成为当前各国研究的重点,通过新检测、新技术的临床应用以实

曹雪涛院士:5个月发表7篇“免疫与癌症”相关论文及综述!

7月19日,Cell子刊Immunity杂志(影响因子24.082)上发表了一篇题为“Post-Translational Modification Control of Innate Immunity”的综述。文章聚焦了翻译后修饰(Post-translational modifications, PTMs)在控制模式识别受体(pattern-recognition receptor, PR

J Clin Res Pediatr Endocrinol:肥胖的儿童、青少年的TSH水平更高

近期有研究表明,肥胖的儿童和青少年与超重或正常体重的同类人群相比,可能有更高水平的促甲状腺激素(TSH)。这些差异的出现,可能是因为肥胖人群的甲状腺自身免疫性疾病的发病率较高所致。阿尔梅里亚Torrecárdenas医院的Emilio García-García博士和同事评估了1317名儿童和青少年(平均年龄8.8岁;女性占48.8%;38.4%的处于青春期),以探究不同体重状态下甲状腺功能和自身

曹雪涛团队揭示抗病毒免疫应答新型表观遗传机制

中国工程院院士曹雪涛团队发现,DNA甲基化酶Dnmt3a能使天然免疫细胞针对病毒感染处于一种敏感状态,一旦识别病毒入侵就可以显著产生干扰素和启动抗病毒天然免疫反应,该发现揭示了抗病毒免疫应答新型表观遗传机制,也为病毒感染性疾病防治提出了新的潜在分子靶标。成果近日发表于《自然—免疫学》。 树突状细胞与巨噬细胞作为关键性天然免疫细胞,能及时识别病毒入侵并启动有效的天然免疫应答以抵御病毒感染,但

组织器官区域免疫特性与疾病重大计划项目指南

组织器官区域免疫特性与疾病重大研究计划2016年度项目指南 中枢和外周免疫器官(如骨髓、胸腺、淋巴结、脾脏等)的免疫学特性,与人体重要疾病高发组织器官(如肝脏、肠道、肺等)的免疫学特性存在较大区别。这些组织器官由于具有独特的结构、生理功能和组织微环境,含有独特的细胞亚群和功能分子,从而形成了独特的区域免疫特性,而且组织器官的区域免疫特性与所在区域的众多疾病的发生发展紧密相关。由于对疾病

Nature:在肠道中,神经细胞是免疫系统的眼睛和耳朵

在一项新的研究中,一个葡萄牙研究小组发现在小鼠肠道中,一种新的过程保护肠道内壁免受炎症和微生物入侵,而且当炎症和微生物入侵出现时,就抵抗它们。而且,最令人吃惊的是,他们还证实这种机制处于肠道神经系统---所谓的“第二大脑”---的控制之下。相关研究结果于2016年7月13日在线发表在Nature期刊上,论文标题为“Glial-cell-derived neuroregulators contr

Baidu
map
Baidu
map
Baidu
map